2012
DOI: 10.1016/j.ejmech.2011.09.004
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 25 publications
(14 citation statements)
references
References 49 publications
0
14
0
Order By: Relevance
“…Benzene derivatives were more potent but less selective than their pyridine analogs while the latter showed more favorable combinations of activity and selectivity. The most interesting compound in this work was compound 78 (Wetzel et al 2012).…”
Section: Figure 16mentioning
confidence: 96%
“…Benzene derivatives were more potent but less selective than their pyridine analogs while the latter showed more favorable combinations of activity and selectivity. The most interesting compound in this work was compound 78 (Wetzel et al 2012).…”
Section: Figure 16mentioning
confidence: 96%
“…In our group we also developed and reported about several classes of non-steroidal 17β-HSD2 inhibitors [10][11][12][13][14], with a strong inhibition of human 17β-hydroxysteroid dehydrogenase type 2 (h17β-HSD2) and a good selectivity toward h17β-HSD1. Since h17β-HSD1 is the biological counterpart of h17β-HSD2, catalyzing the opposite conversion, selectivity toward this enzyme is an important feature to take into consideration.…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, [(dppb)PdCl 2 ] resulted in unsuccessful reaction (Table 1, entry 16). It should be pointed out that since the classic studies by Kumada, [15] [16][17][18][19][20][21] resulted in moderate conversions, thus providing a promising entry point for future studies. We hypothesize that the use of [(PCy 3 ) 2 PdCl 2 ] is optimal in the amide cross-coupling due to combining electron-rich nature of trialkylphosphine with favorable steric properties of PCy 3 .…”
Section: Full Papermentioning
confidence: 99%
“…We demonstrated that the present protocol can be readily employed to access pharmaceutical intermediates by sequential orthogonal aryl halide/amide NÀ C(O) cross-coupling (Scheme 4). Thus, an intermediate in the synthesis 17β-HSD2 inhibitors for the treatment of osteoporosis [18] was prepared in 87% combined yield without isolation of the intermediate amide. Importantly, full selectivity in the biaryl cross-coupling using the conventional Pd (PPh 3 ) 4 was observed in the presence of sensitive amide bond, which was then cross-coupled using [(PCy 3 ) 2 PdCl 2 ] without modification of the reaction conditions.…”
Section: Full Papermentioning
confidence: 99%